
A Phase I study using weekly zzso and zzso was conducted to investigate zzso to determine the maximum tolerated dose zzso of each zzso and, in a preliminary fashion, to determine the zzso activity of the zzso 

zzso and zzso were administered zzso on Days 1, 8, and 15 every 28 zzso The dose levels of zzso and zzso were as zzso Level I, zzso 20 zzso zzso 400 zzso Level II, zzso 30 zzso zzso 400 zzso Level III, zzso 30 zzso zzso 600 zzso Level IV, zzso 36 zzso zzso 600 zzso and Level zzso zzso 36 zzso zzso 800 zzso 

zzso eligible patients were zzso The diagnoses were as zzso Eleven patients had zzso cell lung zzso 3 patients had zzso of the zzso 3 patients had zzso zzso 2 patients had adrenal zzso 5 patients had unknown primary tumors, and 9 patients had zzso zzso zzso percent of patients had received prior zzso The median age was 62 years zzso zzso zzso and the median Eastern Cooperative Oncology Group performance status was 1 zzso zzso Five patients were treated at zzso zzso I and II, 6 patients were treated at zzso zzso III and zzso and 11 patients were treated at zzso Level zzso Grade zzso zzso during zzso I included zzso zzso zzso and zzso zzso zzso consisting of zzso and zzso occurred in three of six patients at zzso Level zzso The combination of zzso 36 zzso and zzso 600 zzso zzso Level zzso was determined as the zzso and was the recommended Phase II zzso Two patients had a partial response: one patient with zzso zzso zzso Level zzso and one patient with zzso cell lung zzso zzso Level zzso 

Overall, weekly zzso and zzso were well zzso Further studies using this combination are planned, including a Phase II trial in patients with advanced zzso cell lung zzso 

